Molina, IsraelMelo, Luísa Helena Perin deAviles, Augusto SaoVieira, Paula Melo de AbreuFonseca, Kátia da SilvaCunha, Lucas MacielCarneiro, Cláudia Martins2020-05-082020-05-082020MOLINA, I. et al. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature. Acta Tropica, v. 201, p. 105218, jan. 2020. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0001706X19303833?via%3Dihub>. Acesso em: 10 fev. 2020.0001-706Xhttp://www.repositorio.ufop.br/handle/123456789/12173Despite more than 100 years since it was firstly described Chagas disease, only two drugs are available to treat Chagas disease: Nifurtimox launched by Bayer in 1965 and benznidazole launched by Roche in 1971. Drug discovery initiatives have been looking for new compounds as an alternative to these old drugs. Although new platforms have been used with the latest technologies, a critical step on that process still relies on the in vivo model. Unfortunately, to date, available animal models have limited predictive value and there is no standardization. With the aim to better understand the role of benznidazole, the current standard of care of Chagas disease, we performed this review. We intend to analyze the influence of the experimental design of the most used animal model, the murine model, in the assessment of the efficacy endpoint.en-USabertoChagas diseaseTrypanosoma cruziClinical trialArtigo publicado em periodicoThis is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/). Fonte: o próprio artigo.https://doi.org/10.1016/j.actatropica.2019.105218